## 1 Title Page

## 2 3 4

3 Article Type: Research Article

- 5 Title: Potential impact of outpatient stewardship interventions on antibiotic exposures of
- 6 bacterial pathogens
- 7
- 8 Authors: Christine Tedijanto,<sup>1</sup> Yonatan H Grad,<sup>2,3</sup> Marc Lipsitch<sup>1,2</sup>
- 9
- 10 Author Affiliations: <sup>1</sup> Center for Communicable Disease Dynamics, Department of
- 11 Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA;
- <sup>2</sup> Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public
- 13 Health, Boston, Massachusetts, USA; <sup>3</sup> Division of Infectious Diseases, Brigham and Women's
- 14 Hospital, Harvard Medical School, Boston, Massachusetts, USA
- 15
- 16 Corresponding Author: Christine Tedijanto, <u>ctedijanto@g.harvard.edu</u>
- 17
- 18 Manuscript Word Count: 4,632
- 19

## 20 Abstract

21 The relationship between antibiotic stewardship and population levels of antibiotic resistance 22 remains unclear. In order to better understand shifts in selective pressure due to stewardship, we 23 use publicly available data to estimate the effect of changes in prescribing on exposures to 24 frequently used antibiotics experienced by potentially pathogenic bacteria that are 25 asymptomatically colonizing the microbiome. We quantify this impact under four hypothetical 26 stewardship strategies. In one scenario, we estimate that elimination of all unnecessary outpatient 27 antibiotic use could avert 6 to 48% (IQR: 17 to 31%) of exposures across pairwise combinations 28 of sixteen common antibiotics and nine bacterial pathogens. All scenarios demonstrate that 29 stewardship interventions, facilitated by changes in clinician behavior and improved diagnostics, 30 have the opportunity to broadly reduce antibiotic exposures across a range of potential 31 pathogens. Concurrent approaches, such as vaccines aiming to reduce infection incidence, are 32 needed to further decrease exposures occurring in "necessary" contexts.

#### 33 Introduction

34 Antibiotic consumption is a known driver of antibiotic resistance. In developed nations, over 80% of antibiotic consumption for human health occurs in the outpatient setting (European 35 36 Centre for Disease Prevention and Control, 2018; Public Health Agency of Canada, 2018; Public 37 Health England, 2017; Swedres-Svarm, 2017), and US-based studies conducted across different 38 subpopulations have estimated that 23-40% of outpatient prescriptions may be inappropriate 39 (Chua, Fischer, & Linder, 2019; Fleming-Dutra et al., 2016; Olesen, Barnett, MacFadden, 40 Lipsitch, & Grad, 2018). Inappropriate antibiotic use leads to increased risk of adverse events 41 (Linder, 2008; Shehab, Patel, Srinivasan, & Budnitz, 2008), disruption of colonization resistance 42 and other benefits of the microbial flora (Buffie & Pamer, 2013; Khosravi & Mazmanian, 2013), 43 and bystander selection for antibiotic resistance, with little to no health gains for the patient. 44 Recent work on bystander selection estimates that, for 8 of 9 potential pathogens of interest, over 45 80% of their exposures to commonly used antibiotic classes in the outpatient setting occur when 46 the organisms are asymptomatically colonizing the microbiome, not causing disease (Tedijanto, 47 Olesen, Grad, & Lipsitch, 2018). A corollary of extensive bystander selection is that reductions 48 in use will prevent antibiotic exposures for species throughout the microbiome.

49

We use publicly available data to quantify potentially avertable exposures of bacterial species to commonly used antibiotics under hypothetical changes in prescribing practice. The set of scenarios included here are intended as thought experiments to explore the upper bounds of avertable antibiotic exposures. Reductions in antibiotic consumption have historically had variable impacts on resistance levels, likely dependent on setting, baseline consumption and resistance patterns, and fitness costs (Andersson & Hughes, 2010; Lipsitch, 2001). In addition,

56	treatment strategies are primarily guided by randomized controlled trials assessing immediate
57	clinical outcomes, with less careful consideration given to the microbiome-wide effect of such
58	decisions. We apply analytical methods to parse out species-level effects of changes in
59	prescribing practice in order to better understand the potential impact of antibiotic stewardship.
60	
61	Methods
62	Scenarios of interest
63	This analysis includes sixteen antibiotics that are frequently prescribed in the outpatient setting
64	and nine potentially pathogenic bacterial species that are commonly carried in the normal human
65	microbiome. For each antibiotic-species pair, we estimate the proportion of antibiotic exposures
66	experienced by that species that could be averted under four hypothetical scenarios. The
67	scenarios range from broad elimination of unnecessary prescribing to focused modifications of
68	antibiotic use for specific indications as follows:
69	1) Eliminate unnecessary antibiotic use across all outpatient conditions.
70	2) Eliminate all antibiotic use for outpatient respiratory conditions for which antibiotics are
71	not indicated.
72	3) Eliminate all antibiotic use for acute sinusitis.
73	4) Prescribe nitrofurantoin for all cases of cystitis in women.
74	We use the results reported by Fleming-Dutra and colleagues as estimates of unnecessary
75	antibiotic use in ambulatory care settings (Fleming-Dutra et al., 2016). In this study, the authors
76	convened a group of experts to estimate the proportion of appropriate antibiotic use by condition
77	and age group based on clinical guidelines. When guidelines could not be used for this task, the
78	rate of appropriate antibiotic prescribing was estimated by benchmarking against the lowest-

79 prescribing US region. Based on the same paper, we consider viral upper respiratory tract 80 infection, influenza, non-suppurative otitis media, viral pneumonia, bronchitis, and allergy and 81 asthma to be outpatient respiratory conditions for which antibiotics are not indicated. 82 83 Antibiotic treatment of acute bacterial sinusitis is currently guideline-recommended (Rosenfeld 84 et al., 2015). However, bacteria are an infrequent cause of acute sinusitis, and due to the self-85 limiting nature of the syndrome, evidence to support antibiotic treatment is weak (Burgstaller, 86 Steurer, Holzmann, Geiges, & Soyka, 2016; Fokkens, Lund, & Mullol, 2007). The cause of 87 sinusitis (whether bacterial, viral, or noninfectious) can be very difficult to distinguish in 88 practice, and as a result of this challenge and others, antibiotics continue to be prescribed at over 89 80% of US outpatient visits with a primary diagnosis of acute sinusitis (Smith et al., 2013). In 90 contrast, antibiotics are always recommended for urinary tract infections (UTIs). Despite being 91 recommended as a second-line therapy for cystitis due to concerns about resistance, 92 fluoroquinolones are the most common treatment, prescribed at 40% of outpatient visits for 93 uncomplicated UTI (Kabbani et al., 2018). We explore the hypothetical scenario of treating all 94 cases of cystitis in women with nitrofurantoin, a recommended first-line therapy with good 95 potency against common uropathogens, low levels of resistance, and decreased risk of collateral 96 damage to the intestinal microbiome due to its propensity to concentrate in the bladder (Gupta et 97 al., 2011; Gupta, Scholes, & Stamm, 1999; Stewardson et al., 2015). Nitrofurantoin is considered 98 clinically appropriate unless the patient has chronic kidney disease, is showing signs of early 99 pyelonephritis, or has had a prior urinary isolate resistant to nitrofurantoin (Hooton & Gupta, 100 2019). In our analysis, we exclude patients with a simultaneous diagnosis of pyelonephritis. We 101 assume that other contraindications are fairly rare in the general population.

## 102 Data sources and methodology

103	Extending our recent work on bystander selection (Tedijanto et al., 2018), we used the 2015
104	National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care
105	Survey (NAMCS/NHAMCS) (National Center for Health Statistics, 2015a, 2015b), the Human
106	Microbiome Project (HMP) (Huttenhower et al., 2012; The Human Microbiome Project
107	Consortium, 2012), and assorted carriage and etiology studies (Bäckhed et al., 2015; Bluestone,
108	Stephenson, & Martin, 1992; Bogaert et al., 2011; Brook, Thompson, & Frazier, 1994; Celin,
109	Bluestone, Stephenson, Yilmaz, & Collins, 1991; Chira & Miller, 2010; Edlin, Shapiro, Hersh, &
110	Copp, 2013; Ginsburg et al., 1985; Gunnarsson, Holm, & Söderström, 1997; Gupta et al., 1999;
111	Jack M. Gwaltney, Scheld, Sande, & Sydnor, 1992; Hammitt et al., 2006; Holgerson, Öhman,
112	Rönnlund, & Johansson, 2015; Susan S. Huang et al., 2009; Jain et al., 2015; Arch G. Mainous,
113	Hueston, Everett, & Diaz, 2006; Pettigrew et al., 2012; Regev-Yochay et al., 2004; Verhaegh et
114	al., 2010; Loretta Wubbel et al., 1999; Yassour et al., 2016) (details in Figure 1 – Source Data
115	File 1) to estimate national outpatient antibiotic exposures by drug, species, and condition.
116	NAMCS/NHAMCS are annual cross-sectional surveys designed to sample outpatient visits in
117	the United States, and up to five diagnoses and thirty medications may be associated with each
118	visit. We used methodology developed by Fleming-Dutra and colleagues (Fleming-Dutra et al.,
119	2016), and applied in other studies (Olesen, Barnett, MacFadden, Lipsitch, et al., 2018), to group
120	diagnosis codes into conditions and link antibiotic prescriptions with the most likely indication.
121	For this analysis, visits with a diagnosis of acute cystitis (ICD-9-CM: 595.0), unspecified cystitis
122	(595.9) or unspecified UTI (599.0), without a concurrent diagnosis of pyelonephritis (590.1,
123	590.8), renal abscess (590.2), or kidney infection (590.9), were considered to be associated with
124	cystitis. In this analysis, we maintain the assumption that one antibiotic prescription is equivalent

125 to one exposure; antibiotic exposures experienced by a given species and associated with a given 126 condition are roughly estimated as the product of antibiotic prescriptions for that condition and 127 species carriage prevalence, which is dependent on disease etiology (target exposures) and 128 asymptomatic carriage prevalence (bystander exposures). For diagnoses where etiology was not 129 readily available, we assumed that none of our species of interest were causative agents. These 130 assumptions have been enumerated in detail in prior work (Tedijanto et al., 2018). We applied 131 proportions of unnecessary antibiotic prescribing by condition and age group estimated by 132 Fleming-Dutra and colleagues based on expert opinion, clinical guidelines, and regional 133 variability in use (Fleming-Dutra et al., 2016). For relevant scenarios (1 and 2), we applied the 134 proportions of unnecessary use evenly across all antibiotic prescriptions. Antibiotics and 135 antibiotic classes are identified by the Lexicon Plus® classification scheme (Lexicon Plus, 136 2008).

137

138 The proportion of avertable antibiotic exposures for each species is defined by Equation 1. The 139 equation adopts previously described notation (Tedijanto et al., 2018) with modifications. A 140 listing of all variables and descriptions can be found in Equation 1 - Figure Supplement 1. Let a 141 represent antibiotic, s represent species, i represent ICD-9-CM diagnosis code, and g represent 142 age group. Throughout the analysis we have weighted outpatient visits to be nationally 143 representative using the sampling and nonresponse weights provided in NAMCS/NHAMCS. Let 144  $X_{as}$  be the number of avertable exposures by antibiotic and species,  $T_{as}$  be the total number of 145 exposures by antibiotic and species,  $d_{aig}$  be the number of prescriptions of antibiotic *a* associated 146 with diagnosis code *i* in age group g,  $p_{sig}$  be the carriage prevalence of species *s* among those 147 with diagnosis code *i* in age group *g*, and  $q_{aig}$  be the proportion of avertable exposures by

148	diagnosis code and age group in the given scenario. For example, in the scenario assessing
149	elimination of all unnecessary antibiotic use, $q_{aig}$ is the proportion of avertable antibiotic use by
150	diagnosis and age group (Fleming-Dutra et al., 2016). Alternatively, in the scenario assessing
151	elimination of non-nitrofurantoin treatment for cystitis, $q_{aig}$ is 1 when a is not nitrofurantoin, i is
152	a diagnosis code associated with cystitis, and the patient is female, and 0 elsewhere. Carriage
153	prevalences $(p_{sig})$ are assumed to be constant within three age groups (under 1 year, 1-5 years,
154	over 5 years old) (Tedijanto et al., 2018), while proportions of avertable antibiotic use $(q_{aig})$ were
155	reported for three different age groups (0-19 years, 20-64 years, 65 years old and over) (Fleming-
156	Dutra et al., 2016). $G$ is the smallest set of age groups that accounts for this granularity (under 1
157	year, 1-5 years, 6-19 years, 20-64 years, 65 years old and over). For antibiotic prescriptions that
158	occurred at visits without any ICD-9-CM diagnosis codes (i=0), we applied the carriage
159	prevalence among healthy individuals.


160 Equation 1. Proportion of avertable exposures by species and antibiotic. Equation 1 – Figure
 161 Supplement 1 includes further details on all variables.
 162


$$\frac{X_{as}}{T_{as}} = \frac{\sum_{g=1}^{G} \sum_{i=0}^{I} d_{aig} \times p_{sig} \times q_{aig}}{\sum_{g=1}^{G} \sum_{i=0}^{I} d_{aig} \times p_{sig}}$$

163

164 In scenarios where unnecessary use is eliminated (1 and 2), we assume that only bystander 165 exposures are affected. Equivalently, this presumes that perfect discrimination between bacterial 166 and non-bacterial etiologies is possible. This results in a slight modification to the numerator of Equation 1 --  $p_{sig}$  is changed to  $p_{s0g}$  as all eliminated exposures would have occurred during 167 168 asymptomatic carriage. For cases where  $e_{sig}$  is 1, we assume zero avertable exposures. In 169 addition, we make slight modifications to  $q_{aig}$  when we estimate the proportion of bacterial cases 170 to be larger than the proportion of necessary prescriptions (Figure 1 – Source Data File 2) 171 (Bluestone et al., 1992; Brook, 2016; Celin et al., 1991). As a sensitivity analysis, we include the

- 172 proportion of avertable exposures for each bacteria-antibiotic pair under Scenario 1 if antibiotic
- 173 use was eliminated equally across both target and bystander exposures (Figure 1 Figure
- 174 Supplement 1). All analysis was conducted in R version 3.6.1.
- 175
- 176 Results
- 177 Results for all four scenarios are depicted in Figure 1.





- 181 outpatient conditions, *B*: all antibiotic use for outpatient respiratory conditions for which
- antibiotics are not indicated, *C*: all antibiotic use for acute sinusitis, or *D*: non-nitrofurantoin
- 183 treatment of cystitis in women was eliminated. Drug class results include prescriptions of all
- 184 antibiotics in that class, as identified by the Lexicon Plus® classification system. Sensitivity and
- 185 other additional analyses are shown in Figure 1 Figure Supplements 1-4.
- 186 Abbreviations: Antibiotics (y-axis): AMX-CLAV=amoxicillin-clavulanate,, MACR/LINC=macrolides/
- 187 lincosamides, TMP-SMX=sulfamethoxazole-trimethoprim; Organisms (x-axis): EC=E. coli, HI=H. influenzae,
- 188 KP=K. pneumoniae, MC=M. catarrhalis, PA=P. aeruginosa, SA=S. aureus, SAg=S. agalactiae, SP=S. pneumoniae,
- 189 SPy=*S. pyogenes*; PY=person-years 190

## 191 Scenario 1

192 We estimate that elimination of unnecessary antibiotic prescriptions across all outpatient 193 conditions would prevent 6 to 48% (IQR: 17 to 31%) of antibiotic-species exposures (Figure 194 1A). The smallest reduction is associated with S. pyogenes exposures to cefdinir and the largest 195 with H. influenzae, E. coli, and P. aeruginosa exposures to azithromycin. If all unnecessary 196 antibiotic use could be prevented, over 30% of exposures to amoxicillin-clavulanate, penicillin, 197 azithromycin, clarithromycin, levofloxacin, and doxycycline across most potential pathogens of 198 interest could be averted. Of particular interest, elimination of all unnecessary prescribing in the 199 outpatient setting could reduce exposures of S. pneumoniae to penicillins and macrolides by 27% 200 and 37%, respectively, and of S. aureus to penicillins and quinolones by 27% and 21%. For E. 201 *coli* and *K. pneumoniae*, approximately one-quarter of exposures to cephalosporins and one-fifth 202 of exposures to quinolones could be averted.

203

204 Scenario 2

205 Scenario 2, elimination of all antibiotic use for outpatient respiratory conditions where 206 antibiotics are not indicated, is a subset of Scenario 1 and accounts for a substantial portion of 207 avertable exposures included in the first scenario. As in Scenario 1, the results are primarily 208 driven by drug and depend on the amount of use of that drug for the affected conditions (in this 209 case, conditions for which antibiotics are not indicated). Pathogen characteristics affecting the 210 proportion of avertable exposures can be better understood by looking across all species for a 211 single drug. For example, we focus on the row for azithromycin. Based on NAMCS/NHAMCS 212 2015, 32% of all azithromycin use is associated with the affected conditions. Since these 213 conditions are never caused by our organisms of interest, the maximum proportion of avertable

exposures for any species is 32%. However, the proportion of avertable exposures is modulated
by the number of azithromycin exposures that occur for treatment of other conditions – for
example, a lower proportion of avertable exposures for *S. pyogenes*, *M. catarrhalis*, and *S. agalactiae* indicates that they have relatively frequent exposure to azithromycin during treatment
of other conditions that are unaffected in this scenario, often both as a bystander and causative
pathogen.

220

221 Scenario 3

In Scenario 3, we explore elimination of all antibiotic use for acute sinusitis. Overall, acute sinusitis accounts for just 3% of prescriptions of our included antibiotic classes, resulting in the low proportions of avertable exposures across most bacteria-antibiotic combinations. However,

225 proportions of avertable exposures are relatively high for amoxicillin-clavulanate and

226 clarithromycin, antibiotics for which a large proportion of their use is due to acute sinusitis (15%

and 9%, respectively). In this scenario, we make the assumption that all use for acute sinusitis is

228 unnecessary. In reality, a small number of cases are truly bacterial and antibiotics are indicated

for patients with persistent, severe or worsening symptoms (Rosenfeld et al., 2015). We explore

230 varying levels of unnecessary use based on etiological data in Figure 1 – Figure Supplement 2

231 (Aitken & Taylor, 1998; Benninger, Holzer, & Lau, 2000; Fleming-Dutra et al., 2016; Sande &

Gwaltney, 2004; Snow, Mottur-Pilson, & Hickner, 2001; Wald, Guerra, & Byers, 1991;

233 Williams, Simel, Roberts, & Samsa, 1992).

234

235

## 237 Scenario 4

238 In this scenario, we consider a program to prescribe only nitrofurantoin for all cases of acute 239 cystitis in women, replacing all other antibiotics that are currently in use. As a result of this 240 change, we estimate that exposures of E. coli and K. pneumoniae to cephalosporins could be 241 reduced by 16% and 17%, respectively, and exposures to quinolones could decrease by 26% and 242 28%. Uniquely in this scenario among the ones we considered, several of our species of interest 243 cause a large proportion of UTI cases (E. coli, K. pneumoniae, and P. aeruginosa). To explore 244 the effects of being a causative pathogen on the proportion of avertable exposures, we focus on 245 the results for ciprofloxacin. Overall, 27% of ciprofloxacin use is associated with acute cystitis in 246 women. Organisms that are not causative pathogens of cystitis have proportions of avertable 247 exposures close to or less than 27%, but a substantially higher proportion of exposures could be 248 averted among causative pathogens - 33%, 36%, and 44% of ciprofloxacin exposures to E. coli, 249 K. pneumoniae, and P. aeruginosa, respectively. Although E. coli is the most common cause of 250 UTIs, its estimated proportion of avertable exposures in this scenario is lower than that of P. 251 aeruginosa, likely due to the larger number of antibiotic exposures incurred by E. coli during 252 asymptomatic carriage.

253

This scenario also allows us to observe the impact of differences in disease incidence, antibiotic use patterns, and carriage prevalence across age groups on the proportion of avertable exposures. For example, *M. catarrhalis* is asymptomatically carried in children much more frequently than in adults. Since cystitis occurs primarily in adults, the proportion of avertable exposures is often lower for *M. catarrhalis* compared to other species due to bystander exposures in children that are largely unaffected by modified prescribing practices for cystitis. This age group effect can be

substantial for antibiotics that are commonly given to children, especially when the antibiotic is also used to treat a condition caused by *M. catarrhalis* (e.g. cefdinir and otitis media), but is less influential for antibiotics that are infrequently prescribed to children, such as ciprofloxacin and levofloxacin.

264

265 Overall, the proportion of avertable exposures is driven by pathogen, syndrome, and prescribing 266 characteristics. Because our organisms of interest experience the vast majority of their antibiotic 267 exposures as bystanders, the metric is largely dependent on the proportion of antibiotic use that is 268 associated with the conditions affected in the given scenario. In a scenario where all antibiotic 269 use for affected conditions is eliminated, this proportion would be equal to the proportion of 270 avertable exposures for organisms exposed to antibiotics only during carriage (never pathogens). 271 Being a causative pathogen for any of the affected conditions increases the proportion of 272 avertable exposures. In contrast, being a causative pathogen for unaffected conditions increases 273 unaffected antibiotic exposures and thus decreases the proportion of avertable exposures. For 274 pathogens responsible for multiple syndromes, both factors may be at play. Finally, 275 asymptomatic carriage prevalence is positively associated with both affected and unaffected 276 antibiotic exposures, and, as a result, its overall effect on the proportion of avertable exposures is 277 dependent on the bacteria-antibiotic combination of interest.

278

## 279 Discussion

We quantify the species-level impact of changes in antibiotic consumption as the proportion of antibiotic exposures experienced by common bacterial pathogens that could be averted under four hypothetical scenarios. In the scenario where unnecessary antibiotic use for all outpatient

conditions is eliminated, we find that up to 48% of exposures (of *H. influenzae, E. coli*, and *P. aeruginosa* to azithromycin) could be avoided. In addition, impact of the intervention across
antibiotics and species is widespread, with half of antibiotic-species pairs expected to experience
a reduction in exposures of over one-fifth (22%). For conditions which require antibiotic
treatment, such as UTIs, switching to antibiotics with decreased collateral damage to the
microbiome, such as nitrofurantoin, may be an effective strategy for reducing antibiotic
exposures across species.

290

291 In three out of four situations we assess, antibiotics are considered entirely unnecessary for some 292 or all cases. In the future, this method may also be extended to measure net changes in exposures 293 resulting from more nuanced scenarios where one antibiotic is substituted for another. We did 294 not assess such changes for nitrofurantoin, as its effects on the microbiome outside of the bladder 295 are thought to be minimal (Stewardson et al., 2015). The reductions in use presented here may be 296 practically infeasible due to challenges including similar clinical presentation of viral and 297 bacterial infections, laboratory processing times that prevent identification of causative 298 pathogens during outpatient visits, individual considerations such as allergies (Sakoulas, Geriak, 299 & Nizet, 2018) or heightened risk of adverse events, misdiagnosis (Filice et al., 2015; Tomas, 300 Getman, Donskey, & Hecker, 2015), and patient-driven demand (Vanden Eng et al., 2003). Even 301 if elimination of unnecessary use were fully realized, our results imply that the majority of 302 species' antibiotic exposures occur in the context of "necessary" antibiotic use. These findings 303 underscore the importance of considering bystander effects and the need for a multi-pronged 304 approach to programs aimed at controlling antibiotic resistance. Rapid diagnostics, diagnostics 305 that accurately discriminate between bacterial and non-bacterial causes, patient education, and

improved decision-making tools and other interventions to motivate changes in clinician behavior can enhance responsible antibiotic consumption and reduce unnecessary antibiotic use; these should be implemented simultaneously with prevention measures such as infection control, access to clean water and sanitation, safe sex interventions, and vaccination, which aim to reduce infection incidence and thus any antibiotic use.

311

312 At the time of this analysis, NHAMCS data from hospital outpatient departments was not

313 available for 2015. In the 2010-2011 NAMCS/NHAMCS data, visits to hospital outpatient

departments accounted for 36% of included sampled visits, but just 9% of all antibiotic mentions.

315 Since the proportions of avertable exposures including and excluding these visits for 2010-2011

316 were similar for Scenario 1 (Figure 1 – Figure Supplement 3), we assumed that the existing 2015

317 data without hospital outpatient department visits was representative of the NAMCS/NHAMCS

318 population for the purposes of our analysis. Certain outpatient encounters are also outside the

319 scope of NAMCS/NHAMCS, including federal facility visits, telephone contacts, house calls,

320 long-term care stays, urgent care, retail clinics, and hospital discharge prescriptions.

321

Additional limitations of the included datasets and method for estimating antibiotic exposures have been previously enumerated (Tedijanto et al., 2018). Notably, the NAMCS/NHAMCS does not provide information to link medications with diagnoses, so we adopted a published tiered system to pair antibiotic use at each visit with the most likely indication (Fleming-Dutra et al., 2016). For visits with multiple diagnoses, all antibiotic use was attributed to the single mostlikely indication. This method tends to overestimate antibiotic use for conditions for which antibiotics are almost always indicated, which may lead to clinically unusual diagnosis-treatment

linkages. In the same way, antibiotic prescriptions are underestimated for diagnoses for which antibiotic use is not indicated, potentially leading to downward bias in avertable exposures for these conditions. Additionally, NAMCS/NHAMCS antibiotic use data does not include prescription details such as duration or dose. Future studies with more granular data may extend the methods presented here to account for such factors.

334

335 At the time of this analysis, Fleming-Dutra et al. remained the most up-to-date source of 336 unnecessary antibiotic prescribing by condition. Recent work with slightly different methods 337 found a lower proportion of inappropriate antibiotic prescriptions overall (23.2% compared to 338 30%) but did not report their estimates by condition (Chua et al., 2019). Although comparable 339 estimates of unnecessary prescribing over time are unavailable, multiple studies have shown that 340 declines in antibiotic use from approximately 2011 to 2016 in the United States have been 341 primarily due to pediatric prescribing, implying that, at least for adults, levels of unnecessary 342 prescribing likely remained similar (Durkin et al., 2018; King, Bartoces, Fleming-Dutra, Roberts, 343 & Hicks, 2019; Klevens et al., 2019; Olesen, Barnett, MacFadden, Lipsitch, et al., 2018). We 344 also assume that the proportion of unnecessary use is constant across all antibiotic use for the 345 same condition as it is difficult to identify specific antibiotic prescriptions that were unwarranted 346 without detailed chart review. A study among outpatients in the Veterans Affairs medical system 347 found that among prescriptions for community-acquired pneumonia, sinusitis, and acute 348 exacerbations of chronic bronchitis, the highest proportion of macrolide use was inappropriate 349 (27%), followed by penicillins (22%) and quinolones (12%) (Tobia, Aspinall, Good, Fine, & 350 Hanlon, 2008). Similar studies are needed to understand which antibiotics are frequently used 351 inappropriately for other indications and settings.

352 Finally, it is important to note that the reduction in antibiotic exposures estimated here does not 353 translate to the same reduction in the prevalence of resistance or in the morbidity and mortality 354 attributable to resistance. Although population-level antibiotic consumption has been positively 355 correlated with levels of antibiotic resistance, the impact of changing consumption is not well-356 understood and is likely to vary widely by bacteria-antibiotic combination (or even strain-357 antibiotic combination) based on resistance mechanisms, fitness costs, and co-selection, among 358 other factors (Andersson & Hughes, 2010; Pouwels et al., 2017). Antibiotic consumption is also 359 highly heterogeneous and the impact of stewardship on resistance may depend on the affected 360 patient populations (Olesen, Barnett, MacFadden, Brownstein, et al., 2018). Additionally, in this 361 analysis, we give each exposure equal weight. However, the selective pressure imposed by a 362 single exposure depends on a number of variables, including pharmacokinetics, 363 pharmacodynamics, distribution of bacteria across body sites, and bacterial population size. For 364 example, we might expect that the probability of resistance scales with population size, and thus 365 that an exposure received by an individual with higher bacterial load will have a larger impact on 366 resistance. Further research, integrating knowledge from clinical, ecological, and evolutionary 367 spheres, is needed to elucidate the relationship between antibiotic use and selective pressures and 368 ultimately between use and resistance at the population level (MacLean & San Millan, 2019). 369 370 Reductions in antibiotic consumption are necessary to preserve the potency of these drugs.

371 Quantifying changes in species-level exposures due to stewardship programs is one more step 372 towards understanding how changes in antibiotic use correspond to antibiotic resistance. The 373 methods presented here may be easily extended to incorporate other data sources, such as claims, 374 or to assess more specific stewardship programs. We show that while improved prescribing

- 375 practices have the potential to prevent antibiotic exposures experienced by bacterial species
- throughout the microbiome, complementary efforts to facilitate appropriate antibiotic
- 377 consumption and decrease overall infection incidence are required to substantially avert
- 378 exposures.

## 379 Acknowledgements

- 380 We thank Dr. Lauri Hicks for her helpful comments on this manuscript.
- 381

## **382** Competing Interests

- 383 ML has received consulting income from Affinivax, Antigen Discovery, Merck, and Pfizer and
- 384 research grants through Harvard School of Public Health from Pfizer and PATH. YHG has
- 385 received consulting income from Merck and GlaxoSmithKline. The authors have no other
- 386 relationships or activities that could appear to have influenced the submitted work.
- 387

## 388 Funding Sources

- 389 This work was supported by Grant U54GM088558 (Models of Infectious Disease Agent Study,
- 390 Center for Communicable Disease Dynamics) from the National Institute of General Medical
- 391 Sciences, Grant R01AI132606 from the National Institute of Allergy and Infectious Diseases (to
- 392 YHG), Grant CK000538-01 from the Centers for Disease Control and Prevention, and the Doris
- 393 Duke Charitable Foundation. CT is supported by Grant T32AI007535 from the National Institute
- 394 of Allergy and Infectious Diseases. The content is solely the responsibility of the authors and
- does not necessarily represent the official views of the National Institute of General Medical
- 396 Sciences, National Institutes of Health, National Institute of Allergy and Infectious Diseases,
- 397 Centers for Disease Control and Prevention, Department of Health and Human Services, or the
- 398 Doris Duke Charitable Foundation.
- 399

## 400 Figure Supplements

401

- 402 *Equation 1 Figure Supplement 1.* Notation, descriptions, and sources for variables in Equation
  403 1.
- 404

*Figure 1 – Figure Supplement 1.* Sensitivity analysis of proportions of avertable exposures
 across all outpatient conditions when proportion of unnecessary use is applied equally across
 target and bystander exposures (Equation 1 without modification).

- 408
- 409 *Figure 1 Figure Supplement 2.* Sensitivity analyses for Scenario 3 (elimination of all antibiotic
  410 use for acute sinusitis).
- 411
- 412 *Figure 1 Figure Supplement 3.* Proportions of avertable exposures under Scenario 1
- 413 (elimination of all unnecessary antibiotic use across outpatient conditions) using 2010-2011
- 414 NAMCS/NHAMCS data with and without NHAMCS outpatient department data.
- 415
- 416

## 417 Source Data Files

- 418
- 419 *Figure 1 Source Data File 1*. Summary of etiology studies.
- 420
- 421 *Figure 1 Source Data File 2.* Modifications to proportions of unnecessary antibiotic
- 422 prescriptions based on published etiology studies and antibiotic use in NAMCS/NHAMCS.
- 423 Modifications were made if the reported proportion of bacterial cases for a given condition
- 424 exceeded the estimated proportion of appropriate prescriptions reported in Fleming-Dutra et al.
- 425
- *Figure 1 Source Data File 3.* Estimated antibiotic class exposures by exposed and causative
   species.
- 428
- 429

#### 430 References

- 431
- 432 Aitken, M., & Taylor, J. A. (1998). Prevalence of Clinical Sinusitis in Young Children Followed Up by Primary
- 433 Care Pediatricians. Archives of Pediatrics & Adolescent Medicine, 152(3), 244–248.
- 434 https://doi.org/10.1001/archpedi.152.3.244
- Andersson, D. I., & Hughes, D. (2010). Antibiotic resistance and its cost: Is it possible to reverse resistance? *Nature Reviews Microbiology*, 8(4), 260–271. https://doi.org/10.1038/nrmicro2319
- 437 Bäckhed, F., Roswall, J., Peng, Y., Feng, Q., Jia, H., Kovatcheva-Datchary, P., ... Wang, J. (2015). Dynamics and
- 438 Stabilization of the Human Gut Microbiome during the First Year of Life. *Cell Host & Microbe*, 17(5),
- 439 690–703. https://doi.org/10.1016/j.chom.2015.04.004
- 440 Benninger, M. S., Holzer, S. E. S., & Lau, J. (2000). Diagnosis and treatment of uncomplicated acute bacterial
- 441 rhinosinusitis: Summary of the Agency for Health Care Policy and Research evidence-based report.
- 442 *Otolaryngology–Head and Neck Surgery*, *122*(1), 1–7. https://doi.org/10.1016/S0194-5998(00)70135-5
- Bluestone, C. D., Stephenson, J. S., & Martin, L. M. (1992). Ten-year review of otitis media pathogens. *The Pediatric Infectious Disease Journal*, *11*(8), S7–S11. https://doi.org/10.1097/00006454-199208001-00002
- 445 Bogaert, D., Keijser, B., Huse, S., Rossen, J., Veenhoven, R., Gils, E. V., ... Sanders, E. (2011). Variability and
- 446 Diversity of Nasopharyngeal Microbiota in Children: A Metagenomic Analysis. *PLoS ONE*, 6(2), e17035.
  447 https://doi.org/10.1371/journal.pone.0017035
- Brook, I. (2016). Microbiology of chronic rhinosinusitis. *European Journal of Clinical Microbiology & Infectious Diseases*, 35(7), 1059–1068. https://doi.org/10.1007/s10096-016-2640-x
- Brook, I., Thompson, D. H., & Frazier, E. H. (1994). Microbiology and Management of Chronic Maxillary Sinusitis.
   *Archives of Otolaryngology–Head & Neck Surgery*, *120*(12), 1317–1320.
- Buffie, C. G., & Pamer, E. G. (2013). Microbiota-mediated colonization resistance against intestinal pathogens.
   *Nature Reviews Immunology*, *13*(11), 790–801. https://doi.org/10.1038/nri3535
- 454 Burgstaller, J. M., Steurer, J., Holzmann, D., Geiges, G., & Soyka, M. B. (2016). Antibiotic efficacy in patients with
- 455 a moderate probability of acute rhinosinusitis: A systematic review. *European Archives of Oto-Rhino-*
- 456 *Laryngology*, 273(5), 1067–1077. https://doi.org/10.1007/s00405-015-3506-z
- 457 Celin, S. E., Bluestone, C. D., Stephenson, J., Yilmaz, H. M., & Collins, J. J. (1991). Bacteriology of Acute Otitis
- 458 Media in Adults. JAMA, 266(16), 2249–2252. https://doi.org/10.1001/jama.266.16.2249

- 459 Chira, S., & Miller, L. G. (2010). *Staphylococcus aureus* is the most common identified cause of cellulitis: A
- 460 systematic review. *Epidemiology and Infection*, 138(3), 313–317.
- 461 https://doi.org/10.1017/S0950268809990483
- 462 Chua, K.-P., Fischer, M. A., & Linder, J. A. (2019). Appropriateness of outpatient antibiotic prescribing among
- 463 privately insured US patients: ICD-10-CM based cross sectional study. *BMJ*, 364(k5092).
- 464 https://doi.org/10.1136/bmj.k5092
- 465 Durkin, M. J., Jafarzadeh, S. R., Hsueh, K., Sallah, Y. H., Munshi, K. D., Henderson, R. R., & Fraser, V. J. (2018).
- 466 Outpatient Antibiotic Prescription Trends in the United States: A National Cohort Study. *Infection Control*
- 467 & Hospital Epidemiology, 39(5), 584–589. https://doi.org/10.1017/ice.2018.26
- Edlin, R. S., Shapiro, D. J., Hersh, A. L., & Copp, H. L. (2013). Antibiotic resistance patterns of outpatient pediatric
  urinary tract infections. *The Journal of Urology*, *190*(1), 222–227.
- 470 https://doi.org/10.1016/j.juro.2013.01.069
- 471 European Centre for Disease Prevention and Control. (2018). *Antimicrobial consumption: Annual epidemiological*472 *report for 2017.* Stockholm.
- 473 Filice, G. A., Drekonja, D. M., Thurn, J. R., Hamann, G. M., Masoud, B. T., & Johnson, J. R. (2015). Diagnostic
- 474 Errors that Lead to Inappropriate Antimicrobial Use. *Infection Control & Hospital Epidemiology*, *36*(8),
- 475 949–956. https://doi.org/10.1017/ice.2015.113
- 476 Fleming-Dutra, K. E., Hersh, A. L., Shapiro, D. J., Bartoces, M., Enns, E. A., File, T. M., ... Hicks, L. A. (2016).
- 477 Prevalence of Inappropriate Antibiotic Prescriptions Among US Ambulatory Care Visits, 2010-2011.
- 478 *JAMA*, *315*(17), 1864–1873. https://doi.org/10.1001/jama.2016.4151
- Fokkens, W., Lund, V., & Mullol, J. (2007). European position paper on rhinosinusitis and nasal polyps 2007. A
  summary for otorhinolaryngologists. *Rhinology*, 45(97).
- 481 Ginsburg, C. M., McCracken, G. H., Crow, S. D., Dildy, B. R., Morchower, G., Steinberg, J. B., & Lancaster, K.
- 482 (1985). Seroepidemiology of the Group-A Streptococcal Carriage State in a Private Pediatric Practice.
- 483 *American Journal of Diseases of Children*, 139(6), 614–617.
- 484 https://doi.org/10.1001/archpedi.1985.02140080084039
- Gunnarsson, R. K., Holm, S. E., & Söderström, M. (1997). The prevalence of beta-haemolytic streptococci in throat
  specimens from healthy children and adults: Implications for the clinical value of throat cultures.

487 *Scandinavian Journal of Primary Health Care*, *15*(3), 149–155.

- 488 https://doi.org/10.3109/02813439709018506
- 489 Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., ... Soper, D. E. (2011). International
- 490 Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in
- 491 Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for
- 492 Microbiology and Infectious Diseases. *Clinical Infectious Diseases*, 52(5), e103–e120.
- 493 https://doi.org/10.1093/cid/ciq257
- 494 Gupta, K., Scholes, D., & Stamm, W. E. (1999). Increasing prevalence of antimicrobial resistance among
- 495 uropathogens causing acute uncomplicated cystitis in women. *JAMA*, 281(8), 736–738.
- 496 https://doi.org/10.1001/jama.281.8.736
- 497 Gwaltney, Jack M., Scheld, W. M., Sande, M. A., & Sydnor, A. (1992). The Microbial Etiology and Antimicrobial
- 498 Therapy of Adults with Acute Community-Acquired Sinusitis—A 15-Year Experience at the University of
- 499 Virginia and Review of Other Selected Studies. Journal of Allergy and Clinical Immunology, 90(3), 457-

500 462. https://doi.org/10.1016/0091-6749(92)90169-3

- 501 Hammitt, L. L., Bruden, D. L., Butler, J. C., Baggett, H. C., Hurlburt, D. A., Reasonover, A., & Hennessy, T. W.
- 502 (2006). Indirect Effect of Conjugate Vaccine on Adult Carriage of <i>Streptococcus pneumoniae<\i>An
- 503 Explanation of Trends in Invasive Pneumococcal Disease. *The Journal of Infectious Diseases*, 193(11),
- 504 1487–1494. https://doi.org/10.1086/503805
- Holgerson, P. L., Öhman, C., Rönnlund, A., & Johansson, I. (2015). Maturation of oral microbiota in children with
  or without dental caries. *PLoS ONE*, *10*(5), 1–20. https://doi.org/10.1371/journal.pone.0128534
- Hooton, T. M., & Gupta, K. (2019). Acute simple cystitis in women. In *UpToDate, Post, TW (Ed)*. Retrieved from
   https://www.uptodate.com/contents/acute-simple-cystitis-in-women
- 509 Huang, Susan S., Hinrichsen, V. L., Stevenson, A. E., Rifas-Shiman, S. L., Kleinman, K., Pelton, S. I., ...
- 510 Finkelstein, J. A. (2009). Continued Impact of Pneumococcal Conjugate Vaccine on Carriage in Young
  511 Children. *Pediatrics*, 124(1), e1–e11. https://doi.org/10.1542/peds.2008-3099
- 512 Huttenhower, C., Gevers, D., Knight, R., Abubucker, S., Badger, J. H., Chinwalla, A. T., ... White, O. (2012).
- 513 Structure, function and diversity of the healthy human microbiome. *Nature*, 486(7402), 207–214.
- 514 https://doi.org/10.1038/nature11234

- 515 Jain, S., Self, W. H., Wunderink, R. G., Fakhran, S., Balk, R., Bramley, A. M., ... Finelli, L. (2015). Community-
- 516 Acquired Pneumonia Requiring Hospitalization among U.S. Adults. *New England Journal of Medicine*,
- 517 373(5), 415–427. https://doi.org/10.1056/NEJMoa1500245
- 518 Kabbani, S., Hersh, A. L., Shapiro, D. J., Fleming-Dutra, K. E., Pavia, A. T., & Hicks, L. A. (2018). Opportunities
- 519 to Improve Fluoroquinolone Prescribing in the United States for Adult Ambulatory Care Visits. *Clinical*
- 520 Infectious Diseases, 67(1), 134–136. https://doi.org/10.1093/cid/ciy035
- 521 Khosravi, A., & Mazmanian, S. K. (2013). Disruption of the gut microbiome as a risk factor for microbial

522 infections. *Current Opinion in Microbiology*, *16*(2), 221–227. https://doi.org/10.1016/j.mib.2013.03.009

- King, L. M., Bartoces, M., Fleming-Dutra, K. E., Roberts, R. M., & Hicks, L. A. (2019). Changes in US Outpatient
   Antibiotic Prescriptions from 2011-2016. *Clinical Infectious Diseases*. https://doi.org/10.1093/cid/ciz225
- 525 Klevens, R. M., Caten, E., Olesen, S. W., DeMaria, A., Troppy, S., & Grad, Y. H. (2019). Outpatient antibiotic
- 526 prescribing in Massachusetts, 2011-2015. *Open Forum Infectious Diseases*, 6(5), ofz169.
- 527 https://doi.org/10.1093/ofid/ofz169
- 528 Lexicon Plus. (2008). Retrieved from https://www.cerner.com/solutions/drug-database
- 529 Linder, J. A. (2008). *Editorial Commentary:* Antibiotics for Treatment of Acute Respiratory Tract Infections:
- 530 Decreasing Benefit, Increasing Risk, and the Irrelevance of Antimicrobial Resistance. *Clinical Infectious*
- 531 Diseases, 47(6), 744–746. https://doi.org/10.1086/591149
- 532 Lipsitch, M. (2001). The rise and fall of antimicrobial resistance. *Trends in Microbiology*, *9*(9), 438–444.
- 533 https://doi.org/10.1016/S0966-842X(01)02130-8
- MacLean, R. C., & San Millan, A. (2019). The evolution of antibiotic resistance. *Science*, *365*(6458), 1082–1083.
  https://doi.org/10.1126/science.aax3879
- 536 Mainous, Arch G., Hueston, W. J., Everett, C. J., & Diaz, V. A. (2006). Nasal Carriage of Staphylococcus aureus
- and Methicillin-Resistant *S aureus* in the United States, 2001-2002. *The Annals of Family Medicine*, 4(2),
- 538 132–137. https://doi.org/10.1370/afm.526
- National Center for Health Statistics. (2015a). *National Ambulatory Medical Care Survey—Public-use data file and documentation*. Retrieved from ftp://ftp.cdc.gov/pub/Health Statistics/NCHS/Datasets/NAMCS

- 541 National Center for Health Statistics. (2015b). *National Hospital Ambulatory Medical Care Survey—Public-use*
- 542 *data file and documentation*. Retrieved from
- 543 ftp://ftp.cdc.gov/pub/Health\_Statistics/NCHS/Datasets/NHAMCS
- 544 Olesen, S. W., Barnett, M. L., MacFadden, D. R., Brownstein, J. S., Hernández-Díaz, S., Lipsitch, M., & Grad, Y.
- 545 H. (2018). The distribution of antibiotic use and its association with antibiotic resistance. *ELife*, 7(e39435).
- 546 https://doi.org/10.7554/eLife.39435.001
- Olesen, S. W., Barnett, M. L., MacFadden, D. R., Lipsitch, M., & Grad, Y. H. (2018). Trends in outpatient antibiotic
  prescribing practice among US older adults, 2011-2015: An observational study. *BMJ*, 362, k3155.
- 549 https://doi.org/10.1136/bmj.k3155
- 550 Pettigrew, M. M., Laufer, A. S., Gent, J. F., Kong, Y., Fennie, K. P., & Metlay, J. P. (2012). Upper respiratory tract
- 551 microbial communities, acute otitis media pathogens, and antibiotic use in healthy and sick children.

552 *Applied and Environmental Microbiology*, 78(17), 6262–6270. https://doi.org/10.1128/AEM.01051-12

- Pouwels, K. B., Batra, R., Patel, A., Edgeworth, J. D., Robotham, J. V., & Smieszek, T. (2017). Will co-trimoxazole
  resistance rates ever go down? Resistance rates remain high despite decades of reduced co-trimoxazole
  consumption. *Journal of Global Antimicrobial Resistance*, *11*, 71–74.
- 556 https://doi.org/10.1016/j.jgar.2017.07.013
- 557 Public Health Agency of Canada. (2018). Canadian Antimicrobial Resistance Surveillance System 2017 Report.
- Public Health England. (2017). English Surveillance Programme for Antimicrobial Utilisation and Resistance
   (ESPAUR) 2017.
- 560 Regev-Yochay, G., Dagan, R., Raz, M., Carmeli, Y., Shainberg, B., Derazne, E., ... Rubinstein, E. (2004).
- Association Between Carriage of *Streptococcus pneumoniae* and *Staphylococcus aureus* in Children.
   *JAMA*, 292(6), 716–720. https://doi.org/10.1001/jama.292.6.716
- 563 Rosenfeld, R. M., Piccirillo, J. F., Chandrasekhar, S. S., Brook, I., Kumar, K. A., Kramper, M., ... Corrigan, M. D.
- 564 (2015). Clinical Practice Guideline (Update): Adult Sinusitis. Otolaryngology–Head and Neck Surgery,
- 565 *152*(2S), S1–S39. https://doi.org/10.1177/0194599815572097
- 566 Sakoulas, G., Geriak, M., & Nizet, V. (2018). Is a Reported Penicillin Allergy Sufficient Grounds to Forgo the
- 567 Multidimensional Antimicrobial Benefits of  $\beta$ -Lactam Antibiotics? *Clinical Infectious Diseases*, 68(1),
- 568 157–164. https://doi.org/10.1093/cid/ciy557

- 569 Sande, M. A., & Gwaltney, J. M. (2004). Acute Community-Acquired Bacterial Sinusitis: Continuing Challenges
- 570 and Current Management. *Clinical Infectious Diseases*, 39, S151–S158. https://doi.org/10.1086/421353
- 571 Shehab, N., Patel, P. R., Srinivasan, A., & Budnitz, D. S. (2008). Emergency Department Visits for Antibiotic-
- 572 Associated Adverse Events. *Clinical Infectious Diseases*, 47(6), 735–743. https://doi.org/10.1086/591126
- 573 Smith, S. S., Evans, C. T., Tan, B. K., Chandra, R. K., Smith, S. B., & Kern, R. C. (2013). National burden of
- antibiotic use for adult rhinosinusitis. *Journal of Allergy and Clinical Immunology*, *132*(5), 1230–1232.
  https://doi.org/10.1016/j.jaci.2013.07.009
- Snow, V., Mottur-Pilson, C., & Hickner, J. M. (2001). Principles of Appropriate Antibiotic Use for Acute Sinusitis
  in Adults. *Annals of Internal Medicine*, *134*(6), 495. https://doi.org/10.7326/0003-4819-134-6-200103200-
- 578 00016
- 579 Stewardson, A. J., Gaïa, N., François, P., Malhotra-Kumar, S., Delémont, C., Martinez de Tejada, B., ... Lazarevic,

580 V. (2015). Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract

- 581 infections: A culture-free analysis of gut microbiota. *Clinical Microbiology and Infection*, 21(4), 344.e1-
- 582 344.e11. https://doi.org/10.1016/j.cmi.2014.11.016
- 583 Swedres-Svarm. (2017). Consumption of antibiotics and occurrence of antibiotic resistance in Sweden. Public
- 584 Health Agency of Sweden and National Veterinary Institute.
- 585 Tedijanto, C., Olesen, S. W., Grad, Y. H., & Lipsitch, M. (2018). Estimating the proportion of bystander selection
- 586 for antibiotic resistance among potentially pathogenic bacterial flora. *Proceedings of the National Academy*
- 587 of Sciences, 115(51), E11988–E11995. https://doi.org/10.1073/pnas.1810840115
- 588 The Human Microbiome Project Consortium. (2012). A framework for human microbiome research. *Nature*,
- 589 *486*(7402), 215–221. https://doi.org/10.1038/nature11209
- 590 Tobia, C. C., Aspinall, S. L., Good, C. B., Fine, M. J., & Hanlon, J. T. (2008). Appropriateness of antibiotic
- 591 prescribing in veterans with community-acquired pneumonia, sinusitis, or acute exacerbations of chronic
- 592 bronchitis: A cross-sectional study. *Clinical Therapeutics*, *30*(6), 1135–1144.
- 593 https://doi.org/10.1016/j.clinthera.2008.06.009
- 594 Tomas, M. E., Getman, D., Donskey, C. J., & Hecker, M. T. (2015). Overdiagnosis of Urinary Tract Infection and
- 595 Underdiagnosis of Sexually Transmitted Infection in Adult Women Presenting to an Emergency
- 596 Department. Journal of Clinical Microbiology, 53(8), 2686–2692. https://doi.org/10.1128/JCM.00670-15

- 597 Vanden Eng, J., Marcus, R., Hadler, J. L., Imhoff, B., Vugia, D. J., Cieslak, P. R., ... Besser, R. E. (2003).
- 598 Consumer Attitudes and Use of Antibiotics. *Emerging Infectious Diseases*, 9(9), 1128–1135.

599 https://doi.org/10.3201/eid0909.020591

- 600 Verhaegh, S. J. C., Lebon, A., Saarloos, J. A., Verbrugh, H. A., Jaddoe, V. W. V., Hofman, A., ... van Belkum, A.
- 601 (2010). Determinants of *Moraxella catarrhalis* colonization in healthy Dutch children during the first 14
- 602 months of life. *Clinical Microbiology and Infection*, 16(7), 992–997. https://doi.org/10.1111/j.1469-
- 603 0691.2009.03008.x
- Wald, E. R., Guerra, N., & Byers, C. (1991). Upper Respiratory Tract Infections in Young Children: Duration of and
   Frequency of Complications. *Pediatrics*, 87(2), 129–133.
- Williams, J. W., Simel, D. L., Roberts, L., & Samsa, G. P. (1992). Clinical Evaluation for Sinusitis. *Annals of Internal Medicine*, *117*(9), 705–710. https://doi.org/10.7326/0003-4819-117-9-705
- Wubbel, Loretta, Muniz, L., Ahmed, A., Trujillo, M., Carubelli, C., McCoig, C., ... McCracken, G. H. (1999).
- Etiology and treatment of community-acquired pneumonia in ambulatory children. *The Pediatric Infectious Disease Journal*, 18(2), 98–104.
- 611 Yassour, M., Vatanen, T., Siljander, H., Hämäläinen, A.-M., Härkönen, T., Ryhänen, S. J., ... Xavier, R. J. (2016).
- 612 Natural history of the infant gut microbiome and impact of antibiotic treatments on strain-level diversity
- 613 and stability. *Science Translational Medicine*, 8(343), 129–139.
- 614 https://doi.org/10.1126/scitranslmed.aad0917
- 615
- 616
- 617
- 618
- 619
- 620
- 621

- ( . . .
- 623
- 624

## 625 Equation 1 – Figure Supplement 1. Notation, descriptions, and sources for variables

- 626 in Equation 1.
- 627


Variable	Definition	Source
d <sub>aig</sub>	Number of prescriptions (using nationally representative weights) of antibiotic <i>a</i> associated with ICD9-CM diagnosis code <i>i</i> in age group <i>g</i>	NAMCS/NHAMCS 2015
esig	Proportion of cases of condition defined by ICD9-CM diagnosis code $i$ in age group $g$ caused by species $s$	Published etiology studies (see Figure 1 – Source Data File 1)
<b>p</b> s0g	Asymptomatic carriage prevalence of species <i>s</i> in age group <i>g</i>	Human Microbiome Project (HMP) and published carriage studies
Psig	Carriage prevalence of species <i>s</i> among individuals diagnosed with ICD9-CM code <i>i</i> in age group <i>g</i>	$e_{sig} + (1 - e_{sig})p_{s0g}$
<b>q</b> aig	Proportion of prescriptions of antibiotic <i>a</i> associated with ICD9-CM diagnosis code <i>i</i> in age group <i>g</i> that are avertable under the given scenario	Based on article by Fleming- Dutra et al. (Fleming-Dutra et al., 2016) with adjustments as described in Figure 1 – Source Data File 2; note that in the nitrofurantoin-specific scenario, this variable is 1 for all antibiotic use for cystitis (ICD codes defined in main text) in women of all age groups, and 0 otherwise
Xas	Number of exposures of antibiotic <i>a</i> experienced by species <i>s</i> that are avertable under the given scenario	$\sum_{g=1}^{G} \sum_{i=0}^{I} d_{aig} \times p_{sig} \times q_{aig}$
T <sub>as</sub>	Total number of exposures of antibiotic <i>a</i> experienced by species <i>s</i>	$\sum_{g=1}^{G} \sum_{i=0}^{I} d_{aig} \times p_{sig}$

628

## 630 **Figure 1 – Figure Supplement 1.** Sensitivity analysis of proportions of avertable

631 exposures across all outpatient conditions when proportion of unnecessary use is

- applied equally across target and bystander exposures (Equation 1 without
- 633 modification).
- 634



635 636

637 Abbreviations: Antibiotics (y-axis): AMX-CLAV=amoxicillin-clavulanate, MACR/LINC=macrolides/

638 lincosamides, TMP-SMX=sulfamethoxazole-trimethoprim; Organisms (x-axis): EC=E. coli, HI=H.

639 influenzae, KP=K. pneumoniae, MC=M. catarrhalis, PA=P. aeruginosa, SA=S. aureus, SAg=S.

640 agalactiae, SP=S. pneumoniae, SPy=S. pyogenes; PY=person-years


## 643 **Figure 1 – Figure Supplement 2.** Sensitivity analyses for Scenario 3 (elimination of all

644 antibiotic use for acute sinusitis).

### 645 A. Use estimates of unnecessary prescribing for acute sinusitis from Fleming-Dutra et al. Based on

646 Fleming-Dutra et al. (Fleming-Dutra et al., 2016), we estimate that the proportion of unnecessary

647 antibiotic prescriptions for acute sinusitis is 18%, 100%, and 34% for individuals who are 0-19, 20-64, and 648 over 65 years old, respectively (see Figure 1 – Source Data File 2).




649

#### 650 B. Use estimates of bacterial etiology to approximate necessary antibiotic use for acute sinusitis.

The following upper bound estimates for the proportion of acute sinusitis cases with bacterial etiology

652 were used: 2% for adults and 13% for children (applied to 0-19 year old age group) (Sande & Gwaltney,

653 2004; Snow et al., 2001; Wald et al., 1991).




#### 655 C. Use estimates of bacterial etiology among those presenting to primary care clinics to

approximate necessary antibiotic use. Patients visiting the clinic are likely to have more persistent,

657 severe, or worsening symptoms, which may be indications of bacterial etiology. Studies have estimated

that approximately 38% of adults and 17% of children (upper bounds) visiting primary care for symptoms

659 of acute upper respiratory tract infection have bacterial rhinosinusitis (Aitken & Taylor, 1998; Benninger et al., 2000; Williams et al., 1992).




664 Abbreviations: Antibiotics (y-axis): AMX-CLAV=amoxicillin-clavulanate, MACR/LINC=macrolides/

665 lincosamides, TMP-SMX=sulfamethoxazole-trimethoprim; *Organisms (x-axis):* EC=*E. coli*, HI=*H.* 

666 influenzae, KP=K. pneumoniae, MC=M. catarrhalis, PA=P. aeruginosa, SA=S. aureus, SAg=S.

667 agalactiae, SP=S. pneumoniae, SPy=S. pyogenes; PY=person-years

- 670 **Figure 1 Figure Supplement 3.** Proportions of avertable exposures under Scenario 1
- 671 (elimination of all unnecessary antibiotic use across outpatient conditions) using 2010-
- 672 2011 NAMCS/NHAMCS data with (*left*) and without (*right*) NHAMCS outpatient
- 673 department data.



- 675 Abbreviations: Antibiotics (y-axis): AMX-CLAV=amoxicillin-clavulanate, MACR/LINC=macrolides/
- 676 lincosamides, TMP-SMX=sulfamethoxazole-trimethoprim; Organisms (x-axis): EC=E. coli, HI=H.
- 677 influenzae, KP=K. pneumoniae, MC=M. catarrhalis, PA=P. aeruginosa, SA=S. aureus, SAg=S.
- 678 agalactiae, SP=S. pneumoniae, SPy=S. pyogenes; PY=person-years
- 679

## 680 **Figure 1 – Source Data File 1.** Summary of etiology studies.

Publication	Study description	Etiology results
Bacteriology of Acute Otitis Media in Adults (Celin et al., 1991)	34 outpatients aged 18 years or older presenting at the emergency department and diagnosed with acute otitis media; middle-ear aspirates were collected for culture	H. influenzae: 26% M. catarrhalis: 3% S. aureus: 3% S. pneumoniae: 21% S. pyogenes: 3%
Ten-year review of otitis media pathogens (Bluestone et al., 1992)	2807 effusions from children with acute otitis media were collected	H. influenzae: 23% M. catarrhalis: 14% S. aureus: 1% P. aeruginosa: 1% S. pneumoniae: 35% S. pyogenes: 3%
The microbial etiology and antimicrobial therapy of adults with acute community-acquired sinusitis: A fifteen-year experience at the University of Virginia and review of other selected studies (Gwaltney et al., 1992)	339 adult patients with acute community-acquired sinusitis; sinus aspirates were collected prior to treatment	To estimate the proportion of acute sinusitis cases caused by each organism, we multiplied the proportion of bacterial cultures in which each organism was identified (shown below) by the proportion of all acute sinusitis cases estimated to be bacterial in nature (2%) (Fokkens et al., 2007): <i>H. influenzae</i> : 35% <i>M. catarrhalis</i> : 4% <i>S. aureus</i> : 3% <i>S. pneumoniae</i> : 41%
Microbiology and Management of Chronic Maxillary Sinusitis (Brook et al., 1994)	68 patients aged 18 to 67 years who underwent the Caldwell-Luc procedure for chronic sinusitis and whose cultures showed bacterial growth; specimens were taken from the infected sinus during surgery	<i>E. coli</i> : 2.9% <i>H. influenzae</i> : 4.4% <i>K. pneumoniae</i> : 2.9% <i>M. catarrhalis</i> : 11.8% <i>S. aureus</i> : 11.8% <i>S. agalactiae</i> : 5.9% <i>S. pneumoniae</i> : 5.9% <i>S. pyogenes</i> : 7.4%
Increasing Prevalence of Antimicrobial Resistance Among Uropathogens Causing Acute Uncomplicated Cystitis in Women (Gupta et al., 1999)	4802 women aged 18 to 50 years with an outpatient diagnosis of acute cystitis; urine samples were collected	<u>Female</u> <i>E. coli</i> : 86% <i>Klebsiella</i> spp.: 3%
Etiology and treatment of community-acquired pneumonia in ambulatory children (Wubbel et al., 1999)	174 ambulatory patients age 6 months to 16 years with radiographic and clinical evidence of pneumonia; blood, nasopharyngeal, and pharyngeal samples were collected	S. pneumoniae: 27%

Staphylococcus aureus is the most common identified cause of cellulitis: a systematic review (Chira & Miller, 2010)	808 patients with cellulitis who were included in 16 studies published between 1966 and 2006; studies were eligible for inclusion if they used needle aspiration and/or punch biopsy and excluded if they pertained to ocular, odontogenic, pelvic, or surgical site-associated cellulitis	E. coli: 0.4% H. influenzae: 0.1% P. aeruginosa: 0.5% S. aureus: 8% S. agalactiae: 0.5% S. pyogenes: 4.3%
Antibiotic Resistance Patterns of Outpatient Pediatric Urinary Tract Infections (Edlin et al., 2013)	25,418 urinary isolates from patients younger than 18 years in the outpatient setting from 195 United States hospitals in The Surveillance Network	<u>Female</u> <i>E. coli</i> : 83% <i>Klebsiella</i> spp.: 4% <i>P. aeruginosa</i> : 2% <u>Male</u> <i>E. coli</i> : 50% <i>Klebsiella</i> spp.: 10% <i>P. aeruginosa</i> : 7%
Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults (Jain et al., 2015)	2259 patients who were hospitalized for community- acquired pneumonia (based on radiographic evidence) and had specimens for both bacterial and viral testing; specimens may have been taken from blood, acute- phase serum, urine, nasopharynx, oropharynx, sputum, pleural fluid, endotracheal aspirate, or broncho- alveolar-lavage samples	H. influenzae: 0.6% Pseudomonas spp.: 0.4% S. aureus: 1.6% S. pneumoniae: 5.1% S. pyogenes: 0.3%

Figure 1 – Source Data File 2. Modifications to proportions of unnecessary antibiotic
 prescriptions based on published etiology studies and antibiotic use in
 NAMCS/NHAMCS. Modifications were made if the estimated proportion of bacterial

cases for a given condition exceeded the estimated proportion of appropriate

687 prescriptions reported in Fleming-Dutra et al. (Fleming-Dutra et al., 2016).

Age group	Fleming-Dutra estimate	New estimate	Explanation
Pharyngitis			
0-19 years old	34%	Pharyngitis: 47%; Strep throat: 0%	Assuming that all strep-associated use of our antibiotics of interest
20-64 years old	75%	Updated to 51% overall; Pharyngitis: 100%; Strep throat: 0%	(based on NAMCS/NHAMCS) was necessary, we estimated the proportion of non-strep pharyngitis antibiotic use that would have to be eliminated to maintain the overall estimate reported by Fleming-Dutra et al. (Fleming-Dutra et al., 2016).
>64 years old	NA (assume 0%)	NA (assume 0%)	No change.
Sinusitis			
0-19 years old	9%	Acute: 18%; Chronic: 0%	While acute sinusitis is rarely bacterial, bacteria are believed to play a much more prominent role in
20-64 years old	51%	Updated to 40% overall; Acute: 100%; Chronic: 0%	the etiology of chronic sinusitis (Brook, 2016). Thus, we assume that antibiotic use would only be eliminated from acute sinusitis and
>64 years old	16%	Acute: 34%; Chronic: 0%	maintain the overall estimate of unnecessary use reported by Fleming-Dutra et al.(Fleming-Dutra et al., 2016) when possible.
Suppurative otitis	media		
0-19 years old	10%	10%	No change. Approximately 84% of pediatric cases were found to have bacterial growth (Bluestone et al., 1992), so 10% is a reasonable estimate for avertable use.
20-64 years old	33%	26%	Based on an etiology study in adults, only 26% of cases were found to have no bacterial growth (Celin et al., 1991).
>64 years old	NA (assume 0%)	NA (assume 0%)	No change.

# 689 **Figure 1 – Source Data File 3.** Estimated antibiotic class exposures by exposed and 690 causative species.

691

The following tables contain the estimated number of annual antibiotic exposures (in 100,000s) in the outpatient setting in the United States by the species being exposed (y-axis) and the species that is the cause of antibiotic use (x-axis). The values in each table, excluding the "Other" and "Overall" columns were calculated using the following expression:

4

697

$$\sum_{i=1}^{G} \sum_{i=0}^{I} d_{aig} \times e_{s_c ig} \times p_{s_e 0g}$$

698

Let *a* represent antibiotic class,  $s_c$  represent causative species,  $s_e$  represent exposed species, *i* represent ICD-9-CM diagnosis code, and *g* represent age group (under 1 year, 1-5 years, 6-19 years, 20-64 years, 65 years old and over). Then,  $d_{aig}$  is the number of prescriptions of antibiotic class *a* associated with diagnosis code *i* in age group *g*,  $e_{s_cig}$  is the proportion of cases with diagnosis code *i* that are estimated to be caused by causative species  $s_c$  in age group *g*, and  $p_{s_e0g}$  is the healthy carriage prevalence of exposed species  $s_e$  among individuals in age group *g*. When  $s_c$  and  $s_e$  are the same organism,  $p_{s_e0g}$  is set to 1. For each variable, we use the same data sources and estimated to discuss the main text

(NAMCS/NHAMCS 2015, Human Microbiome Project, and published literature).
 The diagonals, shaded in light gray, are "target" antibiotic exposures for the pathogen of interest; in other
 words, these are antibiotic exposures that the organism experienced because it was causing disease.

709words, these are antibiotic exposures that the organism experienced because it was causing disease.710The "Overall" column is all exposures to the antibiotic class of interest experienced by each species and711is equivalent to  $T_{as}$  in Equation 1 of the main text. The "Other" column is the difference between the712"Overall" column and the sum of the remaining columns. Note that this column represents exposures due713to non-bacterial causes as well as bacterial organisms other than our nine potential pathogens of interest.

The "Any antibiotic" table includes all prescriptions for drugs classified as antibiotics based on the Lexicon Plus® Therapeutic Classification Scheme (*Lexicon Plus*, 2008). Any drug with a Level 1 description of "anti-infectives", but with a Level 2 description that was not "amebicides", "antihelmintics", "antifungals", "antimalarial agents", or "antiviral agents" was included as an antibiotic. The "Any included antibiotic class" table includes all prescriptions for drugs in the classes shown in the following tables. Antibiotic classes were defined using the Level 2 categories in Lexicon Plus®.

These tables are designed to facilitate a better understanding of the "nuts and bolts" of this work and to enable calculation of other metrics of interest. For example, the proportion of bystander exposures as calculated by the authors in an earlier paper (Tedijanto et al., 2018) for any given antibiotic and species pair can be calculated as one minus the target exposures (diagonal value) over the "Overall" value. These tables can also be used to understand how interventions focused on a single species (e.g. vaccines) may reduce antibiotic exposures experienced by another species.

- 728
- 729
- 730

Any	anti	bi	ioti	С
-----	------	----	------	---

Causative specie

	Causative species											
		E. coli	H. influenzae	K. pneumoniae	M. catarrhalis	P. aeruginosa	S. aureus	S. agalactiae	S. pneumoniae	S. pyogenes	Other	Overall
	E. coli -	150.2	25.1	7.7	15.9	4.2	12.5	3.6	34.5	43.5	1838.4	2135.6
Exposed species	H. influenzae -	103.9	31	7.9	16	4.4	12.9	3.7	34.4	44.3	1892.7	2151.2
	K. pneumoniae -	11.5	4.2	11.4	2.7	0.5	1.5	0.4	6.2	5.4	220.8	264.7
	M. catarrhalis -	4.9	7.3	0.4	19.6	0.5	1.1	0.3	12.2	6	139	191.3
	P. aeruginosa -	2.8	0.5	0.2	0.3	6.1	0.3	0.1	0.6	1.1	50.3	62.4
	S. aureus -	18.8	5.3	1.4	3.4	0.8	18.2	0.7	7.5	8.2	349.4	413.9
	S. agalactiae -	4.2	1.6	0.3	1	0.2	0.6	5.2	2.4	2.1	80.6	98.2
	S. pneumoniae -	39.2	13.3	3	8.5	1.8	5.1	1.4	40.3	19.1	743.6	875.4
	S. pyogenes -	7.1	1.3	0.5	0.8	0.3	0.8	0.2	1.6	60.8	125.3	198.8

#### Any included antibiotic class

	Causative species										
	E. coli	H. influenzae	K. pneumoniae	M. catarrhalis	P. aeruginosa	S. aureus	S. agalactiae	S. pneumoniae	S. pyogenes	Other	Overall
E. co	li - 143.3	23.8	7.3	15	4	11.6	3.3	32.8	42.9	1042.9	1327
H. influenza	99.2	29.5	7.6	15.1	4.1	11.9	3.4	32.8	43.7	1072.1	1319.4
K. pneumonia	e- 11	4	10.9	2.5	0.5	1.4	0.4	6	5.3	126.1	168.1
M. catarrhal	s- 4.7	6.9	0.4	18.5	0.4	1	0.3	11.6	5.9	88.8	138.5
M. catarrhal P. aeruginos	a - 2.7	0.5	0.2	0.3	5.8	0.3	0.1	0.6	1.1	28.2	39.8
Od X M S. aureu	s- 18	5.1	1.4	3.2	0.8	16.9	0.6	7.2	8.1	198.3	259.5
S. agalactia	e - 4	1.5	0.3	1	0.2	0.5	4.9	2.3	2.1	46.6	63.3
S. pneumonia	e - 37.4	12.6	2.9	8	1.7	4.8	1.4	38.4	18.8	427.4	553.4
S. pyogene	s - 6.7	1.2	0.5	0.8	0.3	0.8	0.2	1.5	59.9	70.5	142.5

733 734

#### Penicillins

		Causative species E. coli H. influenzae K. pneumoniae M. catarrhalis P. aeruginosa S. aureus S. agalactiae S. pneumoniae S. pyogenes Other										
		E. coli	H. influenzae	K. pneumoniae	M. catarrhalis	P. aeruginosa	S. aureus	S. agalactiae	S. pneumoniae	S. pyogenes	Other	Overall
	E. coli -	2.7	13.7	0.8	8.5	0.4	3.9	1.4	18.9	23.6	247.9	321.7
Exposed species	H. influenzae -	2	16.3	0.8	8.5	0.4	3.9	1.4	18.8	23.8	253.1	329.1
	K. pneumoniae -	0.3	2.5	1.1	1.5	0.1	0.5	0.2	3.7	3.1	32	44.9
	M. catarrhalis -	0.3	4.6	0.1	9.9	0.2	0.6	0.2	7.4	4.6	34.3	62.2
	P. aeruginosa -	<0.1	0.3	<0.1	0.2	0.5	0.1	<0.1	0.3	0.6	6.3	8.3
	S. aureus -	0.4	3	0.1	1.9	0.1	5.3	0.3	4.3	4.5	47.9	67.8
	S. agalactiae -	0.1	0.9	<0.1	0.6	<0.1	0.2	2	1.4	1.3	12.3	18.8
	S. pneumoniae -	0.9	7.7	0.3	4.8	0.3	1.7	0.6	21.3	11.1	109.1	157.9
	S. pyogenes -	0.1	0.7	<0.1	0.4	<0.1	0.2	0.1	0.8	31.5	15.9	49.8

Macrolides/lincosamides	Macro	lides/	lincosami	des
-------------------------	-------	--------	-----------	-----

Causative specie

	Causative species										
	E. coli	H. influenzae	K. pneumoniae	M. catarrhalis	P. aeruginosa	S. aureus	S. agalactiae	S. pneumoniae	S. pyogenes	Other	Overall
E. coli -	3.3	4.1	0.6	3	0.2	3	1	5.7	3.9	264.9	289.7
H. influenzae -	2.3	5.6	0.6	3	0.2	3.1	1.1	5.8	4	272.8	298.4
K. pneumoniae -	0.2	0.6	0.9	0.4	<0.1	0.4	0.1	1	0.5	31.8	36
M. catarrhalis -	0.1	0.7	<0.1	4.1	<0.1	0.2	<0.1	1.4	0.4	19.6	26.6
M. catarrhalis -	0.1	0.1	<0.1	0.1	0.2	0.1	<0.1	0.1	0.1	7.3	8.1
Od S. aureus -	0.4	0.9	0.1	0.6	<0.1	4.5	0.2	1.2	0.7	50.4	59.1
S. agalactiae -	0.1	0.2	<0.1	0.2	<0.1	0.1	1.5	0.3	0.2	11.6	14.3
S. pneumoniae -	0.8	1.9	0.2	1.3	0.1	1.2	0.4	7.3	1.6	106.9	121.8
S. pyogenes -	0.2	0.2	<0.1	0.2	<0.1	0.2	0.1	0.3	5.6	18.1	24.9

#### Quinolones

	Causative species										
	E. coli	H. influenzae	K. pneumoniae	M. catarrhalis	P. aeruginosa	S. aureus	S. agalactiae	S. pneumoniae	S. pyogenes	Other	Overall
E. coli	61.3	0.7	2.6	0.5	1.4	0.5	0.2	1	0.3	168.7	237.2
H. influenzae	42.1	1	2.7	0.5	1.5	0.5	0.2	1	0.3	174.3	224.1
K. pneumoniae	4.5	0.1	3.9	0.1	0.2	0.1	<0.1	0.1	<0.1	19.1	28.1
M. catarrhalis	1.4	0.1	0.1	0.7	0.1	<0.1	<0.1	0.2	<0.1	7.2	9.8
N. catarrhalis	1.2	<0.1	0.1	<0.1	2.1	<0.1	<0.1	<0.1	<0.1	4.8	8.2
OC X S. aureus	7.6	0.1	0.5	0.1	0.3	0.8	<0.1	0.2	0.1	31.5	41.1
S. agalactiae	1.6	<0.1	0.1	<0.1	0.1	<0.1	0.3	<0.1	<0.1	6.9	9.1
S. pneumoniae	15.5	0.3	1	0.2	0.5	0.2	0.1	1.3	0.1	65	84.3
S. pyogenes	2.9	<0.1	0.2	<0.1	0.1	<0.1	<0.1	0.1	0.5	11.9	15.8

738 739

#### Cephalosporins

		oopnalo	opornio											
				Causative species										
		E. coli	H. influenzae	K. pneumoniae	M. catarrhalis	P. aeruginosa	S. aureus	S. agalactiae	S. pneumoniae	S. pyogenes	Other	Overall		
	E. coli -	38.3	4.6	1.7	2.4	1.1	2.4	0.4	6.6	14	185.7	257.3		
Exposed species	H. influenzae -	26.8	5.6	1.8	2.4	1.1	2.5	0.4	6.5	14.5	190.8	252.3		
	K. pneumoniae -	3	0.7	2.5	0.4	0.1	0.3	<0.1	1.1	1.6	21.9	31.9		
	M. catarrhalis -	1.8	1.4	0.1	2.8	0.1	0.2	<0.1	2.5	0.9	15.7	25.6		
	P. aeruginosa -	0.7	0.1	<0.1	<0.1	1.6	0.1	<0.1	0.1	0.4	5	8.1		
Expo	S. aureus -	4.9	0.9	0.3	0.5	0.2	3.6	0.1	1.4	2.6	35	49.5		
	S. agalactiae -	1.1	0.3	0.1	0.2	0.1	0.1	0.6	0.5	0.6	8.3	11.7		
	S. pneumoniae -	10.4	2.5	0.7	1.4	0.5	1	0.1	7.5	5.6	76	105.5		
	S. pyogenes -	1.8	0.2	0.1	0.1	0.1	0.2	<0.1	0.3	20.7	12.6	36.2		

Tetracyc	lines
----------	-------

Causative species

	Causative species											
	_	E. coli	H. influenzae	K. pneumoniae	M. catarrhalis		S. aureus		S. pneumoniae	S. pyogenes	Other	Overall
	E. coli -	0.7	0.3	0.1	0.1	<0.1	0.3	0.1	0.3	0.2	78.6	80.6
H. ir	nfluenzae -	0.5	0.4	0.1	0.1	<0.1	0.3	0.1	0.3	0.2	81.3	83.3
K. pne	eumoniae -	0.1	<0.1	0.1	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	8.8	9.1
S M. c	atarrhalis -	<0.1	<0.1	<0.1	0.2	<0.1	<0.1	<0.1	<0.1	<0.1	2.8	3
Exposed species	eruginosa -	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	2.2	2.3
Expo	S. aureus -	0.1	0.1	<0.1	<0.1	<0.1	0.5	<0.1	<0.1	<0.1	14.6	15.4
S. a	igalactiae -	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	0.1	<0.1	<0.1	3.2	3.3
S. pne	eumoniae -	0.2	0.1	<0.1	<0.1	<0.1	0.1	<0.1	0.4	0.1	29.9	30.9
S. p	oyogenes -	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	0.3	5.6	6

#### Sulfamethoxazole-trimethoprim

		Causative species										
	E. coli	H. influenzae	K. pneumoniae	M. catarrhalis	P. aeruginosa	S. aureus	S. agalactiae	S. pneumoniae	S. pyogenes	Other	Overall	
E. c	oli - 23.1	0.3	1.1	0.5	0.6	1.5	0.3	0.4	0.8	67	95.5	
H. influenza	ie - 16.1	0.5	1.1	0.5	0.6	1.5	0.3	0.4	0.9	68.8	90.5	
K. pneumonia	ie - 1.8	<0.1	1.6	0.1	0.1	0.2	<0.1	<0.1	0.1	9	12.9	
M. catarrha	is - 0.9	<0.1	0.1	0.7	<0.1	0.1	<0.1	<0.1	<0.1	8.1	10	
M. catarrha	a - 0.4	<0.1	<0.1	<0.1	0.9	<0.1	<0.1	<0.1	<0.1	1.7	3.2	
od S. aurer	ıs - 2.9	0.1	0.2	0.1	0.1	2.2	0.1	0.1	0.2	13.3	19.1	
S. agalactia	ie - 0.7	<0.1	<0.1	<0.1	<0.1	0.1	0.4	<0.1	<0.1	3.2	4.5	
S. pneumonia	ie - 6.1	0.1	0.4	0.2	0.2	0.6	0.1	0.6	0.3	29	37.6	
S. pyogen	es - 1.1	<0.1	0.1	<0.1	<0.1	0.1	<0.1	<0.1	1.2	4.3	6.9	

743 744

#### Nitrofurantoin

			Causative species									
		E. coli	H. influenzae	K. pneumoniae	M. catarrhalis	P. aeruginosa	S. aureus	S. agalactiae	S. pneumoniae	S. pyogenes	Other	Overall
	E. coli -	13.8	<0.1	0.6	<0.1	0.3	<0.1	<0.1	<0.1	<0.1	30.1	44.9
Exposed species	H. influenzae -	9.5	<0.1	0.6	<0.1	0.3	<0.1	<0.1	<0.1	<0.1	31.2	41.6
	K. pneumoniae -	1	<0.1	0.9	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	3.4	5.3
	M. catarrhalis -	0.3	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	1.1	1.4
	P. aeruginosa -	0.3	<0.1	<0.1	<0.1	0.5	<0.1	<0.1	<0.1	<0.1	0.9	1.6
Expo	S. aureus -	1.7	<0.1	0.1	<0.1	0.1	<0.1	<0.1	<0.1	<0.1	5.6	7.5
	S. agalactiae -	0.4	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	1.2	1.6
	S. pneumoniae -	3.5	<0.1	0.2	<0.1	0.1	<0.1	<0.1	<0.1	<0.1	11.5	15.4
	S. pyogenes -	0.7	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	2.1	2.9